Lilly
Coverage of Lilly in the Nexus archive.
- STAT+: Moderna launches early trial of Ebola mRNA vaccine
Moderna has launched an early trial of an Ebola mRNA vaccine. The article also mentions earnings reports from Amgen, Gilead Sciences, United Therapeutics, Novo, and Lilly.
- Lilly’s revenue soars 48%, driven by demand for its GLP-1s
Lilly's revenue increased by 48% due to strong demand for its GLP-1 drugs Mounjaro and Zepbound, which are used for treating Type 2 diabetes and weight loss.
- A preventive neurologist shares 2 overlooked dementia risk factors
A preventive neurologist highlights vision and hearing loss as overlooked risk factors for dementia. Research suggests sensory loss may reduce brain stimulation and increase social isolation, contributing to cognitive decline. A 2024 Lancet study estimates nearly half of dementia cases could be prevented by addressing such risk factors.
- STAT+: Is there a pharma mega-merger in the making?
The article discusses the FDA's upcoming decision on Moderna's mRNA flu shot, a renewed debate over 340B rebates, and legal challenges regarding Lilly's insulin pricing. It highlights key developments in the biotech and pharmaceutical sectors.
- Have you seen Lilly? AMBER Alert issued for Tennessee 1-year-old
An AMBER Alert was issued for a missing 1-year-old girl in Franklin County, Tennessee, who is believed to be with her non-custodial mother. The alert was activated on Wednesday afternoon.
- Boy, 14, charged with murder over death of teenager Lilly in Wales
A 14-year-old boy has been charged with murder after the body of a 14-year-old girl was discovered in the Duffryn Park area of Blaina, Wales. Gwent police confirmed the arrest and stated the accused will face court in Newport.
- Boy, 14, charged with murder after teenage girl's body discovered
A 14-year-old boy has been charged with murder after the body of a teenage girl, named Lilly by Gwent Police, was discovered. The police issued an undated handout photo of the missing 14-year-old.
- Obesity drugs approach a major milestone, and Lilly may have a 'game changer' ahead
Obesity drugs are nearing a major milestone, and pharmaceutical company Lilly may have a significant breakthrough ahead. The Investing Club's Homestretch update highlights this development as part of its daily financial analysis.
- Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans
CVS will cover Lilly’s GLP-1 medications, Foundayo (a pill) and Zepbound (an injection), potentially expanding access for millions of Americans.
- STAT+: An AI biotech CEO sets the record straight on AI drug development hype
Peyton Greenside, CEO of BigHat Biosciences, critiques the hype around AI-driven drug development, emphasizing that while AI can rapidly design proteins, the actual drug-making process remains time-consuming and costly. The company, founded in 2019, partners with major pharmaceutical firms like Johnson & Johnson, Merck, and Amgen.
- New data boosts our confidence in Lilly's obesity pill. Plus, Google's new AI features
New data supports Lilly's obesity pill, boosting confidence. The Investing Club releases daily updates, including the Homestretch. Google also introduces new AI features.
- Portal CEO on Lilly Deal for Cancer Biotech CrossBridge
Portal's CEO discussed a potential deal between Lilly and CrossBridge, a cancer biotech company. The collaboration aims to advance cancer treatments through combined expertise.